On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Key Terms

low-grade serous ovarian cancer medical

A slow-growing form of ovarian cancer that arises from the cells lining the ovary and tends to progress more gradually than common types. It matters to investors because its distinct biology often responds differently to standard chemotherapy, creating demand for specialized drugs, diagnostic tests and clinical trials; think of it like a slow-burning engine that needs different tools to fix, which can shape drug development, regulatory review and market opportunity.

kras-mutated medical

KRAS-mutated describes cancer cells that carry a change in the KRAS gene, a key switch that helps control cell growth and division. Because that altered switch can make tumors grow uncontrollably and resist some treatments, knowing a tumor is KRAS-mutated matters to investors: it determines which drugs and tests are needed, affects clinical trial design and approval chances, and shapes potential market demand for targeted therapies and diagnostics.

systemic therapy medical

Treatments that travel through the bloodstream or throughout the body to reach disease sites rather than targeting a single spot—think of a citywide water main delivering resources rather than a local hose. They include drugs given orally, by injection, or infusion and are commonly used for cancers, infections, and autoimmune diseases. Investors care because systemic therapies often address large patient populations, drive long-term drug sales, carry regulatory and safety risks, and shape competitive positioning and pricing in healthcare markets.

externally-led patient-focused drug development regulatory

A process in which patients or patient groups take the lead in describing their experiences, needs, and priorities for a medical treatment, with regulators and drug developers using that input to shape trials and approval decisions. Like customers guiding a product’s design, this patient-led input can change what outcomes are measured, speed or alter development choices, and affect regulatory and market expectations—information investors use to judge a drug’s prospects and potential uptake.

food and drug administration regulatory

A government agency that reviews and regulates medicines, medical devices, food safety, and related products to ensure they are safe and effective for public use. Investors watch its actions like a referee’s calls: approvals, warnings, inspections or recalls can directly affect a product’s ability to reach the market, a company’s sales and costs, and overall business risk and valuation.

oncology medical

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available at LGSOCAwarenessDay.Org, the LGSOC Resource Guide brings together resources from patient advocacy groups, covering topics from diagnosis to survivorship

BOSTON--(BUSINESS WIRE)-- Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed to support patients living with low-grade serous ovarian cancer (LGSOC), a rare and distinct form of ovarian cancer, along with their caregivers and advocates. Available at www.LGSOCAwarenessDay.org, the guide launches in conjunction with World Ovarian Cancer Day, a global effort to raise awareness of all types of ovarian cancer.

Low-Grade Serous Ovarian Cancer Resource Guide

LGSOC is a rare and distinct form of ovarian cancer that is often underrecognized and can be challenging to diagnose and manage. Patients frequently face delays in diagnosis, have limited access to disease-specific resources, and need to navigate complex treatment decisions. The LGSOC Resource Guide was created to help address these gaps by bringing together trusted educational materials and community resources into one accessible destination.

“For many people living with LGSOC, finding clear, relevant information can be an ongoing challenge—especially given how different this disease is, including how it responds to treatment,” said Nicole Andrews, chair of the STAAR Low-Grade Serous Ovarian Cancer Foundation. “As both an advocate and a patient, the LGSOC Resource Guide represents another meaningful step forward for our community. We’re not only beginning to see new treatment advances that may give patients more confidence and hope for the future, we’re also building on resources from the broader ovarian cancer patient community to bring together trusted information specific for the LGSOC community.”

In 2023, STAAR Low-Grade Serous Ovarian Cancer Foundation engaged directly with the U.S. Food and Drug Administration (FDA) through a first-ever Externally-led Patient-Focused Drug Development (EL-PFDD) meeting, bringing forward the lived experiences of patients with LGSOC and helping to establish broader recognition of LGSOC as a distinct disease requiring dedicated treatment approaches. This effort reinforced the importance of developing treatments tailored to the unique biology of LGSOC, which differs from high-grade ovarian cancer. This effort was foundational in supporting the first and only treatment currently approved by the U.S. Food and Drug Administration (FDA) for KRAS-mutated recurrent LGSOC following a prior systemic therapy, developed by Verastem Oncology.

“A diagnosis of low-grade serous ovarian cancer can feel overwhelming, with patients often asked to make life-altering decisions in just days. While LGSOC is a rare disease, that rarity does not lessen the need for information, connection, and support—it makes it even more critical,” said Emily Campbell, executive director and co-founder of Not These Ovaries. “The LGSOC Resource Guide meets patients in those moments, helping them move from feeling powerless to becoming active participants in their care.”

The LGSOC Resource Guide has compiled resources from dozens of advocacy organizations, including videos, articles, FAQs, and blog posts covering important topics such as diagnosis, treatment and care decisions, fertility and survivorship considerations, emotional wellbeing and caregiver support. It is designed as a flexible tool that individuals can return to over time, depending on their needs and stage of care.

“The LGSOC Resource Guide represents the power of collaboration across the patient advocacy community. By bringing together organizations from across the ovarian cancer and LGSOC patient advocacy community, the Guide includes resources to help patients and their families access meaningful, relevant information throughout their experience,” said Julissa Viana, senior vice president, corporate communications, investor relations, and advocacy relations at Verastem Oncology. “We are deeply grateful to the patient advocacy groups who contributed to this effort. In rare diseases like LGSOC, progress depends on working together, and this guide is an important step toward making sure no patient feels overlooked or alone and can find the resources they need wherever they are looking.”

This resource guide is intended for informational purposes only and reflects information available at the time of publication. As research and treatment options continue to evolve, content may become outdated. Verastem Oncology and its contributors assume no responsibility or obligation to update or modify any of the information contained in the resource guide. Further, Verastem Oncology and its contributors make no representations or warranties regarding the completeness or accuracy of the information and assume no responsibility for any actions taken based on its content.

The LGSOC Resource Guide is available at www.LGSOCAwarenessDay.org.

About Low-Grade Serous Ovarian Cancer (LGSOC)

LGSOC is a rare ovarian cancer that is insidious and persistent. LGSOC is distinct and different from high-grade serous ovarian cancer (HGSOC) and requires different treatment. LGSOC is highly recurrent and less sensitive to chemotherapy compared to HGSOC. Approximately 6,000-8,000 women in the U.S. and 80,000 worldwide are living with this disease. LGSOC affects younger women with bimodal peaks of diagnosis at ages between 20-30 and 50-60 and has a median survival of approximately ten years. Approximately 70 percent of LGSOC shows RAS pathway-associated mutations, and 30 percent of people with LGSOC have a KRAS mutation. The majority of patients report a negative impact of LGSOC on their mental and physical health, fertility, and long-term quality of life.

About STAAR Low-Grade Serous Ovarian Cancer

STAAR was founded by three women—Alex, Bailey, and Jess—each diagnosed with low-grade serous ovarian cancer (LGSOC). United by their passion to extend lives through research, they launched the first U.S.-based nonprofit dedicated to finding effective treatments for LGSOC. STAAR is governed and run by a volunteer board, half of whom are women with LGSOC. Because STAAR is volunteer-led, nearly every donation dollar directly benefits life-saving research. Volunteers play a vital role in STAAR and serve on committees, the board of directors, lead or help with special projects, help at events, or join monthly volunteer meetings to lend ideas.

About Not These Ovaries

Not These Ovaries is a patient-driven nonprofit dedicated to improving outcomes for those affected by low-grade serous carcinoma (LGSOC) and borderline ovarian tumors (BOT). The organization empowers patients and caregivers by providing disease-specific education, resources on biomarkers and treatment options, and guidance on finding experienced healthcare providers. It also invests in research targeting these understudied areas. 100% of donations go directly to supporting patients and funding research. Learn more at www.nottheseovaries.org.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our commercial and clinical pipelines are focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260508725775/en/

For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com

Source: Verastem Oncology